Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

Part of paid clinical trials in New York, New York.

Sponsor
Icahn School of Medicine at Mount Sinai
Study ID
NCT07675044
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • FeNO Breath Test — DIAGNOSTIC_TEST
    Fractional Exhaled Nitric Oxide (FeNO) test breathing test that measures the amount of nitric oxide in exhaled breath to detect airway inflammation, aiding in the diagnosis and management of asthma

Study Details

This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Participants with Asthma
    Individuals with a pre-existing diagnosis of asthma

Primary Outcome Measure

The proportion of patients with FeNO ≥ 25 ppb [ Time Frame: Day 1 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mount Sinai Health SystemNew YorkNew York10029
Jessica Harris, NP
212-241-5656
Linda Rogers, MD
212-241-5656
Monica Kraft (PRINCIPAL_INVESTIGATOR)

Find similar trials in New York, NY

By condition

Related Studies